Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sawai Group Holdings Co., Ltd. (4887.T)
Osaka, JP
Sawai Group Holdings Co., Ltd., together with its associated companies, focuses on the entire lifecycle of generic medications, from their initial research and development to manufacturing and commercialization. The company's primary operational markets are Japan and the United States. Its diverse portfolio includes generic drugs in numerous dosage forms, such as traditional tablets, orally dissolving tablets, capsules, granular preparations, injectable solutions, transdermal patches, ophthalmic and nasal drops, and syrups. These products address a wide array of medical conditions, encompassing therapeutic areas like cardiovascular health, gastrointestinal disorders, central nervous system ailments, allergies, various cancers, infectious diseases, and hormonal therapies. Key offerings from their extensive product line include atorvastatin, lansoprazole, oseltamivir, pregabalin, and fexofenadine hydrochloride. In Japan, Sawai distributes its generic pharmaceutical products through multiple channels: directly to medical facilities such as hospitals, clinics, and dispensing pharmacies, and indirectly through distributors, retail outlets, and other pharmaceutical manufacturers. For the U.S. market, the company supplies its products to pharmaceutical wholesalers. Sawai Group Holdings Co., Ltd. was established in 1929 and is based in Osaka, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -14.49% | -17.30% | -21.29% | -25.50% | -7.68% | -26.54% | +0.40% | +37.21% | +7.28% | -4.33% | -4.33% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 5 | 0 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.7% Q1'26: +2.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+417.5% ★ Q1'26: +98.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-2.5% Q1'26: +4.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+10.1% Q1'26: +0.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+6.5% Q1'26: +0.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-7.2% ★ Q1'26: +4.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.89× Q1'26: 108.05× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 9 Rev. Ana. 9 EPS Ana. |
Mar 2027 3 Rev. Ana. 3 EPS Ana. |
Mar 2028 7 Rev. Ana. 8 EPS Ana. |
Mar 2029 5 Rev. Ana. 5 EPS Ana. |
Mar 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
187.22B
est: 190.83B (-1.9%)
|
193.82B
est: 195.27B (-0.7%)
|
200.34B
est: 203.60B (-1.6%)
|
176.86B
est: 168.20B (+5.1%)
|
189.02B
est: 188.05B (+0.5%)
|
203.12B
198.59B – 206.58B
+8.0% YoY
|
217.94B
216.32B – 219.56B
+7.3% YoY
|
232.09B
220.10B – 245.00B
+6.5% YoY
|
238.89B
238.79B – 238.98B
+2.9% YoY
|
257.06B
249.20B – 265.46B
+7.6% YoY
|
| EBITDA |
35.75B
est: 27.09B (+32.0%)
|
-20.18B
est: 27.72B (-172.8%)
|
34.87B
est: 28.90B (+20.7%)
|
36.88B
est: 19.25B (+91.6%)
|
19.44B
est: 21.52B (-9.7%)
|
23.25B
22.73B – 23.64B
+8.0% YoY
|
24.94B
24.76B – 25.13B
+7.3% YoY
|
26.56B
25.19B – 28.04B
+6.5% YoY
|
27.34B
27.33B – 27.35B
+2.9% YoY
|
29.42B
28.52B – 30.38B
+7.6% YoY
|
| EBIT |
18.96B
est: 8.91B (+112.9%)
|
-35.74B
est: 9.11B (-492.2%)
|
17.19B
est: 9.50B (+80.9%)
|
18.82B
est: 4.42B (+326.1%)
|
4.20B
est: 4.94B (-14.9%)
|
5.33B
5.21B – 5.42B
+8.0% YoY
|
5.72B
5.68B – 5.77B
+7.3% YoY
|
6.09B
5.78B – 6.43B
+6.5% YoY
|
6.27B
6.27B – 6.28B
+2.9% YoY
|
6.75B
6.54B – 6.97B
+7.6% YoY
|
| Net Income |
12.34B
est: 17.10B (-27.9%)
|
-28.27B
est: 9.89B (-385.9%)
|
12.67B
est: 15.32B (-17.3%)
|
13.70B
est: 15.62B (-12.3%)
|
11.97B
est: 26.95B (-55.6%)
|
13.90B
12.01B – 17.02B
-48.4% YoY
|
19.78B
19.78B – 19.79B
+42.3% YoY
|
21.79B
19.62B – 25.00B
+10.1% YoY
|
22.41B
20.53B – 23.88B
+2.8% YoY
|
24.49B
23.52B – 25.53B
+9.3% YoY
|
| SGA |
34.85B
est: 32.29B (+7.9%)
|
32.50B
est: 33.04B (-1.6%)
|
30.16B
est: 34.45B (-12.5%)
|
23.24B
est: 25.57B (-9.1%)
|
23.52B
est: 28.59B (-17.7%)
|
30.88B
30.19B – 31.41B
+8.0% YoY
|
33.14B
32.89B – 33.38B
+7.3% YoY
|
35.29B
33.46B – 37.25B
+6.5% YoY
|
36.32B
36.31B – 36.33B
+2.9% YoY
|
39.08B
37.89B – 40.36B
+7.6% YoY
|
| EPS |
93.94
est: 137.54 (-31.7%)
|
-215.18
est: 79.52 (-370.6%)
|
96.42
est: 123.80 (-22.1%)
|
131.04
est: 135.12 (-3.0%)
|
17.53
est: 233.08 (-92.5%)
|
114.46
104.01 – 147.41
-50.9% YoY
|
171.35
171.34 – 171.36
+49.7% YoY
|
186.64
169.92 – 216.51
+8.9% YoY
|
189.64
177.84 – 206.86
+1.6% YoY
|
212.13
203.69 – 221.15
+11.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan Opportunities Fund OPPJ | 0.24% | 669.8K | 0.58% |
| 2 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.08% | 455.0K | 0.58% |
| 3 | iShares MSCI Japan Small-Cap ETF SCJ | 0.08% | 199.4K | 0.50% |
| 4 | JPMorgan Diversified Return International Equity ETF JPIN | 0.07% | 238.8K | 0.37% |
| 5 | FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund TLTD | 0.06% | 366.8K | 0.41% |
| 6 | State Street SPDR S&P International Small Cap ETF GWX | 0.06% | 485.3K | 0.40% |
| 7 | Dimensional - International Small Cap ETF DFIS | 0.05% | 3.15M | 0.39% |
| 8 | Schwab Fundamental International Small Company Index ETF FNDC | 0.04% | 1.21M | 0.39% |
| 9 | Xtrackers FTSE Developed ex US Multifactor ETF DEEF | 0.03% | 18.6K | 0.24% |
| 10 | Invesco Global Buyback Achievers UCITS ETF BUYB.L | 0.03% | 55.9K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hiroki Tada | Group Chief Marketing Officer | — | — |
| Ichiro Takahashi | Group Chief Human Resource Officer, Group Chief General Affairs Officer & Chief Branding Officer | — | — |
| Jun Tsujii | General Manager of the Group Finance Department | — | — |
| Mitsuo Sawai | Chairman, President, Group Chief Executive Officer & Group Chief Operating Officer | — | male |
| Motohiko Kimura | Senior Managing Executive Officer | — | male |
| Nobuko Sugimoto | Group Chief Intellectual Property Officer | — | female |
| Seiji Nishimura | Corporate Officer & Group Chief Marketing Officer | — | male |
| Shoji Yokota | Director & Senior Managing Executive Officer | — | male |
| Taku Nakaoka | Corporate Officer, Group Chief Officer of USA Business & GM of Group Strategy Department | — | male |
| Toru Terashima | Senior Executive Officer | — | male |
| Toshiya Hasuo | Group Chief Production Officer | — | male |
| Yasushi Kora | General Manager of Public Relations & Investor Relations Office | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4887.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
